| |
|
| October 2007 |
Avidimer receives Michigan Pre-seed Capital Fund investment from Ann Arbor SPARK |
|
|
| August 2007 |
Avidimer closes Series A venture financing round |
|
|
| April 2007 |
Avidimer names David Repp Vice President of Business Operations |
|
|
| April 2007 |
Avidimer names Deborah Ladenheim Vice President of Project Operations & Regulatory Affairs |
|
|
| Fall 2006 |
Avidimer names Larry Sternson President and CEO |
|
|
Winter 2006 |
Avidimer Therapeutics, Inc. selected to receive $2.25M 21st Century Jobs Fund Commercialization Competition Loan |
|
|
|
|
| Welcome to Avidimer Therapeutics! |
Avidimer Therapeutics develops and commercializes pharmaceuticals, called avidimers, based on proprietary nanotechnology. Avidimers are “smart drugs” designed to maximize damage to disease targets while minimizing collateral damage to healthy tissue. The initial focus of the company is on cancer detection and treatment.
The Company’s lead product candidates feature low development risks, cost efficient development plans, and leverage well-defined clinical development pathways while providing significant partnering potential with the first product candidate expected to enter human clinical trials within several months. |
|
